Boston, MACIK 15839774 filings on record
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeLargest positions by weight
32 positions · Q4 2025
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Praxis Precision Medicines I | 950.0K | $280.00M | 15.9% | −50.0K | Reduced |
| 2 | Bridgebio Oncology Therapeut | 17.88M | $223.84M | 12.7% | 0 | Held |
| 3 | Abivax SA | 1.35M | $182.05M | 10.3% | −600.0K | Reduced |
| 4 |
| 8.27M |
| $151.00M |
| 8.6% |
| −60.0K |
| Reduced |
| 5 | Rapport Therapeutics Inc | 3.03M | $91.85M | 5.2% | −165.0K | Reduced |
| 6 | Bridgebio Pharma Inc | 1.20M | $91.79M | 5.2% | −200.0K | Reduced |
| 7 | Bright Minds Biosciences Inc | 1.06M | $82.67M | 4.7% | 0 | Held |
| 8 | Edgewise Therapeutics Inc | 3.29M | $81.52M | 4.6% | −725.0K | Reduced |
| 9 | Olema Pharmaceuticals Inc | 2.75M | $68.75M | 3.9% | +2.75M | New |
| 10 | Moonlake Immunotherapeutics | 4.36M | $57.40M | 3.3% | +2.36M | Added |
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio